Dados do Resumo

Título

Long-term survival of Multiple Myeloma patients in Brazil

Introdução

Multiple myeloma (MM) is a rare neoplasm. Its incidence in Brazil, in 2020, varies from 2.4/ 1.7/100.000. The five and ten-year survival increased among people between 60 and 70 years old.

Objetivo

To describe the five- and ten- year survival in patients with multiple myeloma in Brazil.

Métodos

The cases were extracted from Oncocentro Foundation. OS was estimated from the date of diagnosis until the date of death or last information. OS were constructed using the Kaplan-Meier method and compared using the log-rank test.

Resultados

Five and ten-year OS for <60 years age was 43.8% and 26.1%; in ≥60 years, OS were 28.2% and 11.0%. Patients with health insurance the five- and ten-year OS were 59.4% and 31.8%, in those in the public system, were 35.3% and 17.2%. Patients with health insurance under 60 years had a five-year OS of 74.5% and ten-year OS of 46.0%, in the public system 46.3% and 27.9%. For those undergoing ASCT, in <60 years it was 64.1% and ten-year OS was 40.0 %. Those who did not undergo a ASCT OS was 36.8% and 21.1% five and ten-year; non-ASCT individuals aged over 60 years with health insurance 56.6%and 24.3% for those in the public system OS was 26.1% and 10.0%.

Conclusões

We observed that long term MM survival has increased in the more recent period. Patients in the public health system had worse survival rates. Therefore, expanding access to diagnosis and treatment could increase the survival and reduce inequalities.

Palavras Chave

multiple myeloma; overall survival;